Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity

Valladales‐Restrepo, Luis Fernando; Sánchez-Ramírez, Nicolás; Usma-Valencia, Andrés Felipe; Gaviria‐Mendoza, Andrés; Machado‐Duque, Manuel Enrique; Machado‐Alba, Jorge Enrique

doi:10.1080/14656566.2023.2178900

Cited by 7 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, patients with overweight/obesity and HUA treated with orlistat lost an average of 2.85 kg of body weight over a 3-month period, which was significantly higher than that of the control group. This is consistent with previous findings [ 12 , 13 ].…”

Section: Discussionsupporting

confidence: 94%

“…Orlistat has been approved by the China National Medical Products Administration for the treatment of obese patients. In clinical trials, orlistat has been shown to be effective in terms of improving obesity and related diseases such as metabolic fatty liver disease [ 12 , 13 ]. However, the effect of orlistat on SUA levels in obese patients remains controversial.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial

Liu,

Lin,

Tao

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

Background Obesity is associated with elevated serum uric acid (SUA) levels and frequent gout flares. Losing weight can reduce the SUA level and gout flares. The effect of orlistat on SUA levels and gout flares in patients with overweight/obesity and hyperuricemia (HUA) has not been extensively studied. This study investigated the effects of orlistat on SUA levels and gout flares compared to placebo in overweight and obese patients with HUA. Methods A total of 72 Chinese patients with overweight/obesity and HUA were randomly divided into a placebo group (35, 48.6%) and an orlistat group (37, 51.4%); the trial lasted 12 weeks. The primary endpoints were the relative changes in body weight, the SUA level, and gout flares in the per-protocol population. Results Orlistat reduced the proportion of patients with gout flares (log-rank P = 0.023, hazard ratio = 0.31, 95% confidence interval 0.11–0.85). There was no significant difference in SUA level between the two groups. The average weight loss of the orlistat group was 2.85 kg, and the average weight loss of the placebo group was 0.76 kg. The weight loss in the orlistat group was significantly greater than that in the control group (P < 0.05). Conclusions This study is the first to demonstrate that orlistat has no significant effect on SUA levels in patients with overweight/obesity and HUA. The utility of orlistat as an adjunct therapy to prevent gout flares during weight loss in patients with HUA was emphasized. Trial registration Clinicaltrials.gov NCT05496075.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial

Liu,

Lin,

Tao

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…The focus has, therefore, shifted to the new anti-obesity medications (AOMs) that have been developed in recent years and which appear to lead to more significant and sustained weight loss in comparison with lifestyle interventions and older AOMs such as orlistat [ 15 , 16 ]. Glucagon-like peptide 1 (GLP-1) agonists, such as semaglutide and liraglutide, improve insulin sensitivity, delay gastric emptying and decrease a person’s appetite [ 17 ].…”

Section: Advances In Endometrial Cancer Preventionmentioning

confidence: 99%

Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment

Baker-Rand,

Kitson

2024

Cancers

View full text Add to dashboard Cite

Endometrial cancer is the sixth commonest cancer in women worldwide, with over 417,000 diagnoses in 2020. The disease incidence has increased by 132% over the last 30 years and is set to continue to rise in response to an ageing population and increasing global rates of obesity and diabetes. A greater understanding of the mechanisms driving endometrial carcinogenesis has led to the identification of potential strategies for primary disease prevention, although prospective evaluation of their efficacy within clinical trials is still awaited. The early diagnosis of endometrial cancer is associated with improved survival, but has historically relied on invasive endometrial sampling. New, minimally invasive tests using protein and DNA biomarkers and cytology have the potential to transform diagnostic pathways and to allow for the surveillance of high-risk populations. The molecular classification of endometrial cancers has been shown to not only have a prognostic impact, but also to have therapeutic value and is increasingly used to guide adjuvant treatment decisions. Advanced and recurrent disease management has also been revolutionised by increasing the use of debulking surgery and targeted treatments, particularly immunotherapy. This review summarises the recent advances in the prevention, diagnosis and treatment of endometrial cancer and seeks to identify areas for future research.

show abstract

“…Orlistat has been approved by China National Medical Products Administration for the treatment of obese patients. In clinical trials, orlistat has been shown to be effective in improving obesity and related diseases such as metabolic fatty liver disease (12,13). However, the effect of orlistat on SUA in obese patients remains controversial.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Orlistat in Patients With Overweight/Obese and Hyperuricemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Liu,

Lin,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Obesity is associated with elevated serum uric acid (SUA) and frequent gout flares. Losing weight can lower SUA and reduce gout flares. The effect of orlistat on SUA and gout flares in patients with overweight/obese and hyperuricemia (HUA) has not been extensively studied. In this study, we investigated the effects of orlistat on SUA and gout flares compared to placebo in overweight or obese patients with HUA. Methods A total of 72 Chinese patients with overweight/obese and HUA were randomly divided into placebo group and orlistat group for 12 weeks. The primary endpoints were relative changes in body weight and SUA, as well as gout flares. Results 72 patients with overweight/obesity and HUA were randomly assigned to placebo group (35, 48.61%) and orlistat group (37, 51.39%). Orlistat was associated with a lower proportion of patients with gout flares (log-rank p = 0.023, hazard rate = 0.31, 95% CI 0.11–0.85). There was no significant difference in SUA level between the two groups. The average weight loss of orlistat group was 2.85kg, which was significantly better than that of control group (P < 0.05). Conclusions This study is the first to demonstrate that orlistat has no direct effect on SUA levels in patients with overweight/obese and HUA. The value of orlistat as an adjunct therapy to prevent gout flares during weight loss in patients with HUA was emphasized. Trial registration: Clinicaltrials.gov NCT05496075

show abstract

Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity

Cited by 7 publications

References 31 publications

Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial

Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial

Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment

Efficacy and Safety of Orlistat in Patients With Overweight/Obese and Hyperuricemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Contact Info

Product

Resources

About